Theravia clinical trials
Acquired by Norgine, Aug 14, 2025 · source ↗
The registry lists 8 studies whose lead sponsor is Theravia. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 1, 2026.
Before and after it joined Norgine
- First submitted before Theravia became part of Norgine
- 8
- First submitted after Theravia became part of Norgine
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Theravia8 studies
Something wrong with this grouping? Tell us on the Norgine page.
Studies
Recruiting first, then most recently updated. Showing 8 of 8. All Norgine studies →
- Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell DiseaseRecruitingNCT06578507Phase 2
Sponsor listed in the registry: Theravia · First submitted before Theravia became part of Norgine
- A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Hydroxycarbamide in Healthy VolunteersCompletedNCT05025072Phase 1
Sponsor listed in the registry: Theravia · First submitted before Theravia became part of Norgine
- SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)CompletedNCT03806452Phase 2
Sponsor listed in the registry: Theravia · First submitted before Theravia became part of Norgine
- ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension StudyActive, not recruitingNCT04707235
Sponsor listed in the registry: Theravia · First submitted before Theravia became part of Norgine
- Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.CompletedNCT05470270Phase 2
Sponsor listed in the registry: Theravia · First submitted before Theravia became part of Norgine
- Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)CompletedNCT02522104Phase 4
Sponsor listed in the registry: Theravia · First submitted before Theravia became part of Norgine
- European Sickle Cell Disease Cohort - HydroxyureaCompletedNCT02516579
Sponsor listed in the registry: Theravia · First submitted before Theravia became part of Norgine
- Plasma DNA and Vascular Remodelling in Patients With Sickle Cell DiseaseCompletedNCT02721472Not applicable
Sponsor listed in the registry: Theravia · First submitted before Theravia became part of Norgine